Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Premarin® Vaginal Cream
Premarin Vaginal · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Premarin® Vaginal Cream | DRUG | - |
| Premarin® oral tablets | DRUG | - |
Inclusion Criteria: * Generally healthy postmenopausal women. * Intact uterus. * Clinical diagnosis of moderate to severe atrophic vaginitis.
Premarin Vaginal is used for atrophic vaginitis, a condition in which the vaginal lining thins and dries, often after menopause. It is a small molecule therapy in the endocrine therapeutic area. It was studied in a Phase 1 trial comparing the vaginal cream with oral Premarin tablets in women with atrophic vaginitis.
Premarin Vaginal is made by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the developer of the product, and the clinical program for atrophic vaginitis was sponsored under that company.
Premarin Vaginal is in Phase 1 development for atrophic vaginitis. The single registered trial, NCT00167921, was a Phase 1 study that has been completed. No active trials are currently listed for this asset, and the completed study enrolled 24 participants.
Premarin Vaginal has been studied in one clinical trial, NCT00167921, titled Study Comparing Premarin Vaginal Cream Versus Premarin Oral Tablets in Atrophic Vaginitis. The trial was a completed Phase 1 study conducted in the United States with 24 enrolled female participants aged 45 years and older.
Yes, Premarin Vaginal is also known as Premarin Vaginal Cream. The two names refer to the same product developed by Pfizer for atrophic vaginitis. The Phase 1 trial NCT00167921 compared the vaginal cream formulation with Premarin oral tablets in women with atrophic vaginitis.